Change from baseline in AD severity assessed through physician-reported persistence with prescribed therapy.

Description of the presence, evolution, and therapeutic management of atopic comorbidities over time based on physician-reported data.

Description of the presence, evolution, and therapeutic management of non-atopic comorbidities over time based on physician-reported data.

Description of the use of psychoactive substances over time based on patient-reported data.

Itch assessment (Worst-Itch Numeric Rating Scale, WI-NRS) will be rated from 0 to 10 on average during the past 7 days, completed by the observing physician after questioning of patient; 0 = no itch and 10 = the worst imaginable itch.

NRS sleep disturbance will be rated from 0 to 10 on average during the past 7 days, completed by the observing physician after questioning of patient; 0 = "sleep not disturbed at all" (best possible sleep) and 10 = "sleep extremely disturbed (worst possible sleep)".

Skin pain NRS will be rated from 0 to 10 on average during the past 7 days prior to the visit. On a scale of 0 to 10, with 0 being 'no skin pain at all' and 10 being 'the worst imaginable skin pain'.

ADCT is a questionnaire to assess patient-self-perceived control of their AD with a total score from 0 to 24; higher scores indicate lower AD control.

DLQI is a 10-item questionnaire to measure dermatology specific quality of life (QoL). DLQI is calculated by adding the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. A score higher than 10 indicates that the patient's life is being severely affected by their skin disease.

The HADS is a 14-item patient-reported outcomes measure used to assess states of anxiety and depression over the past week. It is comprised of 7 items assessing anxiety and depression respectively. A Total score is out of 42 (21 per subscale). Higher scores indicate greater levels of anxiety and/or depression.

CLCI-r instrument determines retrospectively which changes and effects the patients have already experienced due to the disease over their entire disease course.

CLCI-p determines the patient's current situation and thus identifies risk areas in which the patient could experience burdens in the future.

Patient's treatment satisfaction score will be assessed using Patient Global Assessment of Treatment Effect (PGATE). PGATE is an assessment tool used to rate the treatment effect of the medication on atopic dermatitis (AD), with scores ranging from 0 to 4 (0 = poor; 1 = fair; 2 = good; 3 = very good; 4 = excellent), i.e., higher score indicated higher treatment effect.

Evolution of atopic comorbidities over time, assessed through physician-reported status, occurrence of new diagnoses and persistence of existing conditions.

History of healthcare pathway of participant related to AD will be assessed by the physician (if participant had appointment with other healthcare provider for AD).

History of healthcare pathway of participant related to AD will be assessed by the physician (if participant received therapeutic education).

Cost of emollients, hygiene products etc. during the last month of the study visit will be assessed.

Number of sick leaves participant has taken related to AD since the last visit or over the last 6 months.

Overnight hospitalization related to AD since the last visit or over the last 6 months.